Press Releases April 30, 2026 04:20 PM

Tejon Ranch Co. Announces Date for First Quarter 2026 Earnings Release and Conference Call

Tejon Ranch Co. Schedules Q1 2026 Earnings Release and Conference Call for May 7, 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
TRC

Tejon Ranch Co., a diversified real estate development and agribusiness company, announced it will release its Q1 2026 financial results before market open on May 7, 2026, followed by a conference call with executives to discuss recent initiatives and results. The call will be webcast and accessible to investors with Q&A submitted in advance.

Tejon Ranch Co. Announces Date for First Quarter 2026 Earnings Release and Conference Call
TRC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The earnings release and conference call are scheduled for May 7, 2026, with senior management presenting.
  • Tejon Ranch is a major landholder and operates in real estate development and agribusiness sectors.
  • Investors have the opportunity to submit questions prior to the call, facilitating transparency and communication.

TEJON RANCH, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Tejon Ranch Co., or the Company, (NYSE: TRC), a diversified real estate development and agribusiness company, today announced it will release its first quarter 2026 financial results before the market opens on May 7, 2026. In connection with this announcement, the Company will host a conference call on May 7, 2026 at 5:00 p.m. Eastern Time. During the call, President & CEO Matt Walker and CFO Robert Velasquez will provide an update on the Company’s recent initiatives and financial results.

Management will address questions e‐mailed in advance by investors to: IR@tejonranch.com. Questions must be submitted by 2:00 p.m. ET on May 7, 2026.

Webcast
An audio webcast of the conference call will be available through the “Investors” section of the Company’s website at www.tejonranch.com. To listen to the broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register and install any necessary audio software. A replay of the audio webcast will be available for one year on the Company’s website shortly after the conclusion of the call. Details on how to access the call are below.

To dial into the Telephone Conference Call:
Domestic: 1-877-704-4453
International: 1-201-389-0920

Conference Call Playback:
Domestic: 1-844-512-2921
International: 1-412-317-6671
Passcode: 13759630
The full playback can be accessed through Thursday, June 4, 2026.

About Tejon Ranch Co.
Tejon Ranch Co. (NYSE: TRC) is a diversified real estate development and agribusiness Company whose principal asset is its 270,000-acre land holding located approximately 60 miles north of Los Angeles and 30 miles south of Bakersfield.

More information about Tejon Ranch Co. can be found on the Company's website at www.tejonranch.com.

Contact:
Nicholas Ortiz
Senior Vice President, Corporate Communications & Public Affairs
nortiz@TejonRanch.com
(661) 331-0313


Risks

  • The company operates in real estate and agribusiness, sectors sensitive to economic and environmental factors, which could impact future performance.
  • Uncertainty exists around the financial results to be disclosed, which may contain volatile elements due to market conditions or operational challenges.
  • Changes in land use regulations or commodity prices could significantly affect Tejon Ranch's agribusiness and development prospects.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026